Welcome to our dedicated page for Arrowhead Research Corporation news (Ticker: ARWR), a resource for investors and traders seeking the latest updates and insights on Arrowhead Research Corporation stock.
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) is a leading clinical-stage biotechnology company dedicated to developing innovative medicines that address intractable diseases through gene silencing. The company utilizes an extensive array of RNA chemistries and efficient delivery systems to harness the power of RNA interference (RNAi) mechanisms. This approach allows for the rapid, deep, and durable knockdown of target genes, thereby reducing the production of specific proteins that cause diseases.
Arrowhead's groundbreaking therapies are at the forefront of genetic-based treatments, presenting potential life-changing solutions for patients. Notable among their technologies is the Targeted RNAi Molecule (TRiMTM) platform. This platform employs ligand-mediated delivery for tissue-specific targeting while maintaining structural simplicity. The TRiMTM platform is built upon over a decade of research in actively targeted drug delivery, offering advantages such as simplified manufacturing processes and enhanced specificity.
The company's diverse portfolio includes promising treatments for conditions such as Hepatitis B, Alpha-1 Antitrypsin Deficiency, thrombosis and angioedema, clear-cell and renal cell carcinoma, and cardiovascular diseases. Arrowhead is continuously engaged in advancing its clinical programs and forging strategic partnerships to bring its novel therapies to market.
With headquarters in Pasadena, California, Arrowhead Pharmaceuticals remains committed to transforming the landscape of genetic medicine and improving patient outcomes worldwide. Their dedication to scientific innovation and patient care positions them as a pivotal player in the biotechnology sector.
Arrowhead Pharmaceuticals reported fiscal year 2022 results, achieving $243.2 million in revenue, up from $138.3 million in 2021. The company incurred a net loss of $172.7 million or $1.67 per diluted share. Operating expenses rose to $421.7 million compared to $287.3 million the prior year. Despite financial challenges, significant progress was made in clinical trials, with promising interim data on ARO-APOC3 and ARO-ANG3. The balance sheet was bolstered by a $250 million royalty sale and potential future earnings from Amgen.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will hold a webcast and conference call on November 28, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal year ending September 30, 2022. Investors can access the live audio via the company’s website, with a replay available two hours post-call. Arrowhead focuses on developing RNA interference therapies targeting intractable diseases.
Arrowhead Pharmaceuticals has announced that Royalty Pharma has acquired a royalty interest in Amgen's olpasiran for $250 million upfront, plus up to $160 million in additional payments based on milestones. Olpasiran, developed for cardiovascular disease treatment, is approaching Phase 3 trials. Arrowhead retains rights to $400 million in milestone payments related to Amgen's development of olpasiran. This agreement reinforces the potential of olpasiran and supports Arrowhead's investment in its RNAi therapeutic pipeline.
Arrowhead Pharmaceuticals presented new clinical data on RNAi-based therapies ARO-APOC3, ARO-ANG3, and olpasiran at the AHA Scientific Sessions 2022. ARO-APOC3 showed significant decreases in triglycerides by 86% and increases in HDL-C by 99%. ARO-ANG3 reduced triglycerides by 59% and LDL-C by 32%, while olpasiran decreased lipoprotein(a) levels by over 95% in ASCVD patients. The company plans to discuss these findings and its future plans in a virtual event on November 9, 2022.
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) announced on October 4, 2022, the approval of inducement grants for 39 new employees, totaling up to 117,500 restricted stock units. This includes 30,000 restricted stock units awarded to Peter Carignan, the new vice president of clinical operations. The grants, which fall under NASDAQ Listing Rules, are outside existing shareholder-approved equity incentive plans and will vest over four years.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will present interim clinical data on ARO-APOC3 and ARO-ANG3 at the American Heart Association Scientific Sessions 2022 in Chicago, from
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) will participate in several upcoming events in September 2022. Key presentations include:
- ERS International Congress: September 4-6, 2022, by Erik Bush on MMP7 gene silencing.
- Wells Fargo Healthcare Conference: September 7-9, 2022, investor meetings with Vincent Anzalone.
- H.C. Wainwright Global Investment Conference: September 12-14, 2022, fireside chat by Christopher Anzalone.
- Baird Global Healthcare Conference: September 13-14, 2022, also featuring Christopher Anzalone.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) has submitted an application to commence a Phase 1/2a clinical trial for ARO-MMP7, an investigational RNA interference therapeutic targeting matrix metalloproteinase 7 (MMP7) for idiopathic pulmonary fibrosis (IPF). The trial aims to assess safety, tolerability, and pharmacokinetics in healthy volunteers and IPF patients. This initiative expands Arrowhead's clinical pipeline, which includes other lung disease candidates. The trial approval is pending from the local Ethics Committee and the New Zealand Medicines and Medical Devices Safety Authority.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) announced its fiscal Q3 results for the period ending June 30, 2022, revealing a revenue of $32.4 million, down from $45.9 million in Q3 2021. The operating loss increased to $72.9 million, compared to $31.9 million the previous year. Notably, the company published promising Phase 2 clinical results for fazirsiran, with 58% of patients showing fibrosis regression. Arrowhead also initiated clinical studies for ARO-MUC5AC and ARO-RAGE and expanded its team. Cash resources stand at $582.4 million.
Arrowhead Pharmaceuticals (NASDAQ: ARWR) will host a webcast and conference call on August 4, 2022, at 4:30 p.m. ET to discuss its financial results for the fiscal 2022 third quarter ended June 30, 2022. Investors can access the live audio webcast on the Company's website. A replay will be available for 90 days.
Arrowhead develops innovative RNAi-based therapeutics targeting intractable diseases through gene silencing.
FAQ
What is the current stock price of Arrowhead Research Corporation (ARWR)?
What is the market cap of Arrowhead Research Corporation (ARWR)?
What is the primary focus of Arrowhead Pharmaceuticals?
What is RNA interference (RNAi)?
What is the TRiMTM platform?
Which diseases does Arrowhead Pharmaceuticals address?
Where is Arrowhead Pharmaceuticals headquartered?
What are the latest developments at Arrowhead Pharmaceuticals?
How does Arrowhead's technology benefit patients?
What are some advantages of the TRiMTM platform?
Is Arrowhead publicly traded?
How can I invest in Arrowhead Pharmaceuticals?
